bourvis_ESM_3.pdf from Pre-linguistic infants employ complex communicative loops to engage mothers in social exchanges and repair interaction ruptures

Comprehensive results from the linear mixed mode

bourvis_ESM_1.pdf from Pre-linguistic infants employ complex communicative loops to engage mothers in social exchanges and repair interaction ruptures

Complete description of STT in 3 and 6 month-old

Placebo response rates (%) in trials for children and adolescents with major depressive disorder (MDD, number of trials = 23), obsessive compulsive disorder (OCD, number of trials = 7), and other anxiety disorders (AD-non-OCD, number of trials = 10).

<p>ANOVA: <i>F</i> = 7.1, df = 2, <i>p</i> = 0.002. N = total number of youths included in the placebo arms; PBO = Placebo.</p

Placebo response rates in placebo-controlled parallel trials as a function of time of publication for major depressive disorder (MDD), obsessive compulsive disorder (OCD) and other anxiety disorders (AD-non-OCD) in children and adolescents.

<p>PBO = Placebo.</p

Trial flow of the pooled-analysis of placebo-response in RCTs for internalized disorders in children and adolescents (RCT: Randomized controlled trials; PBO: placebo).

<p>Trial flow of the pooled-analysis of placebo-response in RCTs for internalized disorders in children and adolescents (RCT: Randomized controlled trials; PBO: placebo).</p

Placebo response rates in double-blind placebo-controlled trials for internalized disorders in children and adolescents

*<p>and Boulos et al, 1992;</p>**<p>and Berard et al, 2006;</p>a<p>possible superiority of drug vs placebo concerns the primary variable;</p>b<p>these reports are pooled analysis in which individual trials did not reveal significant treatment effect</p><p>N = number of subjects randomized in the study; Q = quality score of the report; CDRS: Children's Depression Rating Scale; CGI: Clinical Global Impression-Severity; HDRS: Hamilton Depression Rating Scale; K-SADS-dep: Schedule for Affective Disorder and Schizophrenia-depression/anhedonia subscore; MADRS: Montgomery-Asberg Depression Rating Scale; CYBOCS: Child Yale-Brown Obsessive Compulsive Scale. Placebo responders: N of responders in the placebo arm/N of subjects randomised in the placebo arm (%)</p

Mother-infant interaction at birth and 2 months postpartum.

<p>Mean composite scores are given from the Coding Interaction Procedure.</p

Socio-demographic, pregnancy, delivery, newborn, and dyad characteristics according to scan soft markers or not.

<p>*Given our exclusion criteria, participants had only minor obstetrical histories (e.g., IVG, caesarean for previous pregnancy) or minor medico-chirurgical histories (e.g., appendicitis, minor allergy).</p><p>**Good = integrated/equilibrate; intermediate = reduced/loss involvement; poor = non-integrated/ambivalent.</p

Diagram flow of the study.

<p>*Ultrasound soft markers included ventriculomegaly (N = 8), increased nuchal translucency (N = 16), Short OPN (N = 4), echogenic bowel (N = 19), echogenic intracardiac focus (N = 2), mild pyelectasis (N = 9), and short femur length (N = 2).</p

Maternal anxiety and depression over time.

<p>Mean scores are given for anxiety and depression (lines). Percentages indicate the number of participants with anxiety (or depression) scores above the scale clinical threshold (bars). T1 = Third trimester during pregnancy, T2 = Birth, T3 = 2 months after birth.</p